Free Trial
NASDAQ:RANI

Rani Therapeutics Q3 2025 Earnings Results & Report

Rani Therapeutics logo
$0.53 +0.00 (+0.21%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-1.58%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rani Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.12 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Rani Therapeutics EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Rani Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rani Therapeutics Q3 2025 Earnings FAQ

Rani Therapeutics (NASDAQ:RANI) reported earnings of -$0.12 per share for Q3 2025, missing the consensus estimate of -$0.09. The report was announced on Thursday, November 6, 2025.

Rani Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Rani Therapeutics (RANI) Expected to Release Earnings on Thursday
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) is a clinical-stage biotherapeutics company developing technology to deliver biologic medicines orally. Its RaniPill platform is designed to transport drugs such as peptides and antibodies through the digestive system and release them into the intestinal wall, with the goal of offering an alternative to injections.

Founded in 2012 and based in San Jose, California, the company develops its delivery platform and evaluates it with drug candidates and potential partner medicines. Rani’s work focuses on addressing challenges that have traditionally made many biologic drugs difficult to administer by mouth.

View Rani Therapeutics Profile